[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100508638":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":24,"locations":33,"responsibleParty":61,"collaborators":65,"id":100,"slug":101,"hasResults":102,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":102,"sex":108,"minAge":109,"maxAge":10,"enrollmentInfo":110,"targetDuration":10,"studyType":113,"phases":10,"briefSummary":114,"conditions":115,"keywords":120,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},{"fullName":5,"class":6},"University of Florence","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Episodic migraine",null,"Patients affected by an episodic pattern migraine(\\\u003C 15 monthly headache days) with or without aura according to ICHD-III criteria.",[13],"Drug: Rimegepant 75 MG Disintegrating Oral Tablet",{"label":15,"type":10,"description":16,"interventionNames":17},"Chronic migraine","Patients affected by chronic migraine according to ICHD-III criteria.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DRUG","Rimegepant 75 MG Disintegrating Oral Tablet","Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks",[15,9],[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Luigi F Iannone, MD","CONTACT","+393896969606","luigifrancesco.iannone@unifi.it",{"name":31,"role":27,"phone":10,"phoneExt":10,"email":32},"Roberto De Icco, MD","roberto.deicco@mondino.it",[34,50],{"facility":35,"status":36,"city":37,"state":10,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"SOD Centro Cefalee e Farmacologia Clinica, AOU Careggi","RECRUITING","Florence","50134","Italy","IT",{"type":42,"coordinates":43},"Point",[44,45],11.24626,43.77925,{"lat":45,"lon":44},[48],{"name":26,"role":27,"phone":10,"phoneExt":10,"email":49},"luigifrancesco.iannone@unimore.it",{"facility":51,"status":36,"city":52,"state":10,"zip":53,"country":39,"countryCode":40,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"IRCCS National Neurological Institute \"C. Mondino\" Foundation","Pavia","27100",{"type":42,"coordinates":55},[56,57],9.15917,45.19205,{"lat":57,"lon":56},[60],{"name":31,"role":27,"phone":10,"phoneExt":10,"email":32},{"type":62,"investigatorFullName":63,"investigatorTitle":64,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Luigi Francesco Iannone","Researcher",[66,67,69,71,73,75,77,80,82,84,86,88,90,92,94,96,98],{"name":51,"class":6},{"name":68,"class":6},"Società Italiana per lo Studio delle Cefalee",{"name":70,"class":6},"Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari",{"name":72,"class":6},"Università degli Studi dell'Aquila",{"name":74,"class":6},"University of Roma La Sapienza",{"name":76,"class":6},"Azienda Ospedaliero Universitaria Policlinico Modena",{"name":78,"class":79},"Ospedale di Piove di Sacco","UNKNOWN",{"name":81,"class":6},"Azienda Ospedaliero-Universitaria di Parma",{"name":83,"class":6},"Azienda Ospedaliera S. Maria della Misericordia",{"name":85,"class":6},"A.O.U. Città della Salute e della Scienza",{"name":87,"class":6},"Cliniche Humanitas Gavazzeni",{"name":89,"class":6},"University of Campania Luigi Vanvitelli",{"name":91,"class":6},"Ospedale Santo Stefano",{"name":93,"class":6},"Azienda Policlinico Umberto I",{"name":95,"class":6},"Auxologico San Luca",{"name":97,"class":6},"Asst Degli Spedali Civili Di Brescia",{"name":99,"class":6},"Carlo Besta Neurological Institute","100508638","gepant-treatments-effectiveness-and-tolerability-gainer-100508638",false,"NCT05903027","Gepant treAtments: EffectIveNess and tolERability (GAINER)","Effectiveness and Tolerability of Rimegepant as Acute Migraine Treatment: a Prospective, Multicentric, Cohort Study (GAINER)","GAINER","Inclusion Criteria:\n\n* Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III).\n* At least 3 MMDs\n* Good compliance to study procedures\n* Availability of headache diary at least of the preceding months before enrollment\n\nExclusion Criteria:\n\n* Subjects with contraindications for use of gepants;\n* Concomitant diagnosis of medical diseases and\u002For comorbidities that, in the Investigator's opinion might interfere with study assessments;\n* medical comorbidities that could interfere with study results;\n* Pregnancy and breastfeeding.","ALL","18 Years",{"count":111,"type":112},100,"ESTIMATED","OBSERVATIONAL","The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of rimegepant as acute migraine treatment in a cohort of episodic or chronic migraine patients.",[116,117,118,119],"Migraine","Migraine With Aura","Migraine Without Aura","Chronic Migraine",[121,122,123,124,125],"Headache","Medication overuse headache","Pain","Gepant","Triptan","2026-01-19",{"date":128,"type":129},"2026-01-21","ACTUAL",{"date":131,"type":129},"2023-06-15",{"date":133,"type":112},"2026-09-15",{"name":5,"class":6},2]